DelveInsight’s “Influenza A Infections Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Influenza A Infections, historical and forecasted epidemiology as well as the Influenza A Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Discover Key Insights into the Influenza A Market with DelveInsight’s In-Depth Report @ Influenza A Market Size
Key Takeaways from the Influenza A Infections Market Report
- In November 2024:- Hoffmann-La- Roche- A Phase IIIb Multicenter, Single-Arm, Open-Label Surveillance Study of Susceptibility to Baloxavir Marboxil in Patients With Influenza. The purpose of this study is to evaluate the pre-treatment and single-dose post treatment susceptibility of baloxavir marboxil in participants aged 1 to
- In November 2024:- ModernaTX Inc.- The study consists of 3 parts. Part A of the study was conducted for the 2022-23 influenza season. Part B of the study was conducted in 2023-24 influenza season. Part C of the study will be conducted in 2024-25 influenza season. The main purpose of the study is to evaluate the safety, reactogenicity, and the humoral immunogenicity of mRNA-1010 and comparator influenza vaccines against homologous influenza A and B strains at Day 29.
- The total vaccinated pool of Influenza A in the United States is approximately 176 million in 2021.
- The total Influenza A positive cases in the United States comprised of 42,580 cases in 2021 and are projected to increase during the study period.
- In the United States, there were (H1N1)pdm09, H3N2, and subtyping not performed 19, 7,405, and 35,156 cases in 2021.
- The leading Influenza A Infections Companies such as Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, and others
- Promising Influenza A Infections Therapies such as CD388, SAB-176, M2SR, VIR-2482, mRNA-1010, GSK3206641A, VXA-A1.1, and others
Stay ahead in the Influenza A Therapeutics Market with DelveInsight’s Strategic Report @ Influenza A Market Outlook
Influenza A Infections Epidemiology
- Total Prevalence of Influenza A Infections
- Prevalent Cases of Influenza A Infections by severity
- Gender-specific Prevalence of Influenza A Infections
- Diagnosed Cases of Episodic and Chronic Influenza A Infections
Download the report to understand which factors are driving Influenza A epidemiology trends @ Influenza A Prevalence
Influenza A Marketed Drugs
- XOFLUZA (baloxavir marboxil): Genentech/Roche
XOFLUZA is a first in class, single-dose oral medicine with an innovative proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies. XOFLUZA is the first in a class of antivirals designed to inhibit the cap-dependent endonuclease protein, which is essential for viral replication.
- RAPIVAB (peramivir injection): BioCryst Pharmaceuticals
RAPIVAB (peramivir injection) is an antiviral drug with activity against influenza virus. It is an inhibitor of influenza virus neuraminidase. RAPIVAB is approved in the United States for the treatment of acute uncomplicated influenza in patients six months and older who have been symptomatic for no more than two days. Efficacy of RAPIVAB is based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza A virus and a limited number of patients infected with influenza B virus.
- FLUZONE QUADRIVALENT: Sanofi
FLUZONE QUADRIVALENT is a quadrivalent inactivated influenza vaccine, produced in the US, containing two type A antigens and two type B antigens in order to provide increased protection against more circulating strains of influenza viruses. FLUZONE QUADRIVALENT/FLUQUADRI is available in 13 countries (including the US) for children aged over six months, adolescents and adults. FLUZONE 0.5ml QIV is the currently licensed standard dose (15 µg/strain) quadrivalent influenza vaccine for ages 6 months and older.
Emerging Influenza A Drugs
- CD388: Cidara Therapeutics
Cidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak platform that couple potent antivirals to a human antibody fragment (Fc). These highly potent, long-acting drug-Fc conjugates (DFCs) directly inhibit viral proliferation while simultaneously engaging the immune system. In addition to the clinical-stage CD388 program for seasonal and pandemic influenza, Cidara is advancing DFC programs to target other life-threatening viruses, such as SARS-CoV-2, and immuno-oncology targets associated with multiple cancers.
- SAB-176: SAb Biotherapeutics
SAB-176 is a quadrivalent broadly neutralizing fully-human polyclonal antibody therapeutic candidate that leverages the human biological immune response in developing the treatment of hospitalized patients with severe seasonal influenza. The novel specifically targeted therapeutic generated from the company’s proprietary technology, the DiversitAb platform, is designed to bind to Type A and Type B influenza viruses. Preclinical data suggest that SAB-176 offers potentially broad protection against diverse influenza strains. A highly potent, polyclonal antibody therapy for severe seasonal influenza could potentially treat severely ill patients and provide protective antibodies for high-risk populations, such as the elderly and immune-compromised. Like vaccines, it can also be modified to address annual strain changes when needed. Preclinical data suggest that SAB-176 offers broad protection against diverse influenza strains.
- VIR-2482: Vir Biotechnology
VIR-2482 is an investigational intramuscularly administered influenza A neutralizing monoclonal antibody. In vitro, it has been shown to cover all major strains of influenza A that have arisen since the 1918 Spanish flu pandemic. VIR-2482 is designed as a universal prophylactic for influenza A. It has the potential to overcome the limitations of current flu vaccines and lead to meaningfully higher levels of protection due to its broad strain coverage and because it does not rely on an individual to create their protective antibody response. VIR-2482, which incorporates Xencor’s Xtend technology, also has been half-life engineered so that a single dose has the potential to last the entire flu season.
Get In-Depth Knowledge on Influenza A Market Trends and Forecasts with DelveInsight @ Influenza A Treatment Market
Influenza A Market Outlook
Influenza, or flu, is a respiratory illness that results from a viral infection. Flu is highly contagious and spreads through respiratory droplets. Most people can be treated for the flu at home. A combination of lifestyle remedies and over-the-counter medication can help relieve symptoms. In temperate climate countries, including the US, influenza activity peaks during winter. Annual seasonal influenza epidemics of variable severity result in significant morbidity and mortality in the US.
Scope of the Influenza A Infections Market Report
- Study Period: 2019–2032
- Coverage: 7MM
- Influenza A Infections Companies: Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, and others
- Influenza A Infections Therapies: CD388, SAB-176, M2SR, VIR-2482, mRNA-1010, GSK3206641A, VXA-A1.1, and others
- Influenza A Infections Therapeutic Assessment: Influenza A Infections current marketed and Influenza A Infections emerging therapies
- Influenza A Infections Market Dynamics: Influenza A Infections market drivers and Influenza A Infections market barriers
Unlock Strategic Insights with DelveInsight’s Comprehensive Influenza A Market Report @ Influenza A Market Drivers and Barriers
Table of Contents
1. Influenza A Infections Market Report Introduction
2. Executive Summary for Influenza A Infections
3. SWOT analysis of Influenza A Infections
4. Influenza A Infections Patient Share (%) Overview at a Glance
5. Influenza A Infections Market Overview at a Glance
6. Influenza A Infections Disease Background and Overview
7. Influenza A Infections Epidemiology and Patient Population
8. Country-Specific Patient Population of Influenza A Infections
9. Influenza A Infections Current Treatment and Medical Practices
10. Influenza A Infections Unmet Needs
11. Influenza A Infections Emerging Therapies
12. Influenza A Infections Market Outlook
13. Country-Wise Influenza A Infections Market Analysis (2019–2032)
14. Influenza A Infections Market Access and Reimbursement of Therapies
15. Influenza A Infections Market Drivers
16. Influenza A Infections Market Barriers
17. Influenza A Infections Appendix
18. Influenza A Infections Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Influenza A Market in the 7MM is expected to expand at a healthy growth rate by 2032, estimated DelveInsight